20/08/2025
Il futuro potrebbe essere meno nero.
Pancreatic cancer is one of the deadliest cancers, often returning within months even after surgery. Now, a personalized mRNA vaccine from BioNTech and Genentech offers new hope. Unlike traditional vaccines, it’s designed after diagnosis, using tumor-specific mutations to train T cells to hunt leftover cancer. In a small trial, half the patients developed strong immune responses years later, most remained cancer-free while relapses surged in non-responders. Remarkably, some patients stayed cancer-free for over three years a rare outcome for this aggressive disease. Though early, the findings suggest mRNA vaccines could transform cancer care, turning the immune system into a powerful, personalized defense.